Module 4: Leukemia Risk and Clonal Hematopoiesis

Of all the features of SDS, the risk of developing leukemia is the one patients and families are most worried about. It is a known risk caused by SDS, specifically the SDS biology learned about in Modules 2 and 3. It is the reason why bone marrow surveillance is a central part of SDS management and care throughout life. This module explains what actually happens in the bone marrow over time in SDS — a process called clonal hematopoiesis — and what researchers have learned about which changes are dangerous and which are not. It also connects to important questions, such as: who needs a transplant and when, what surveillance is best and for whom, and what might gene therapy and other new treatments eventually be able to do. This is the most complex module in the series so far. Take your time watching the video and reading the key concept. The concepts you learned in Modules 2 and 3 will help you. What you will be able to do after this module: * Explain what clonal hematopoiesis means and why it happens in SDS * Describe the difference between “good” clones and “bad” maladaptive clones — and why that distinction matters * Understand what the loss of p53 means for leukemia risk * Explain why bone marrow surveillance is important and what researchers are working to improve * Connect this to decisions patients and families may face — about surveillance frequency, transplant timing, and clinical trial participation * Feel more prepared to discuss these topics with clinicians and researchers